سوق علاج التصلب المتعدد في أوروبا - اتجاهات الصناعة والتوقعات حتى عام 2030

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATION

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 KEY TAKEAWAYS

2.2 ARRIVING AT THE EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET SIZE

2.2.1 VENDOR POSITIONING GRID

2.2.2 TECHNOLOGY LIFE LINE CURVE

2.2.3 TRIPOD DATA VALIDATION MODEL

2.2.4 MARKET GUIDE

2.2.5 MULTIVARIATE MODELLING

2.2.6 TOP TO BOTTOM ANALYSIS

2.2.7 CHALLENGE MATRIX

2.2.8 APPLICATION COVERAGE GRID

2.2.9 STANDARDS OF MEASUREMENT

2.2.10 VENDOR SHARE ANALYSIS

2.2.11 EPIDEMIOLOGY BASED MODEL

2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS

2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES

2.3 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET: RESEARCH SNAPSHOT

2.4 ASSUMPTIONS

3 MARKET OVERVIEW

3.1 DRIVERS

3.2 RESTRAINTS

3.3 OPPORTUNITIES

3.4 CHALLENGES

4 EXECUTIVE SUMMARY

 

5 PREMIUM INSIGHTS

5.1 PESTEL ANALYSIS

5.2 PORTER’S 5 FORCES

6 EPIDEMIOLOGY

6.1 INCIDENCE OF ALL BY GENDER

6.2 TREATMENT RATE

6.3 MORTALITY RATE

6.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL

6.5 PATEINT TREATMENT SUCCESS RATES

7 INDUSTRY INSIGHTS

7.1 PATENT ANALYSIS

7.2 DRUG TREATMENT RATE BY MATURED MARKETS

7.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES

7.4 PATIENT FLOW DIAGRAM

7.5 KEY PRICING STRATEGIES

7.6 KEY PATIENT ENROLLMENT STRATEGIES

7.7 INTERVIEWS WITH HEMATOLOGISTS

7.8 INTERVIEWS WITH ONCOLOGISTS

7.9 INTERVIEWS WITH CANCER ORGANIZATIONS

7.1 OTHER KOL SNAPSHOTS

8 PIPELINE ANALYSIS

8.1 CLINICAL TRIALS AND PHASE ANALYSIS

8.2 DRUG THERAPY PIPELINE

8.3 PHASE III CANDIDATES

8.4 PHASE II CANDIDATES

8.5 PHASE I CANDIDATES

8.6 OTHERS (PRE-CLINICAL AND RESEARCH)

9 REGULATORY FRAMEWORK

10 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, BY TYPE

10.1 OVERVIEW

10.2 RELAPSING–REMITTING MULTIPLE SCLEROSIS (RRMS)

10.3 CLINICALLY ISOLATED SYNDROME (CIS)

10.4 PRIMARY PROGRESSIVE MS (PPMS)

10.5 SECONDARY PROGRESSIVE MS (SPMS)

11 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT

11.1 OVERVIEW

11.2 MEDICATIONS

11.2.1 DISEASE-MODIFYING DRUGS

11.2.1.1. MONOCLONAL ANTIBODY

11.2.1.1.1. MONOCLONAL ANTIBODY, BY TYPE

11.2.1.1.1.1 OCRELIZUMAB

11.2.1.1.1.2 NATALIZUMAB

11.2.1.1.1.3 DACLIZUMAB

11.2.1.1.1.4 OTHERS

11.2.1.1.2. MONOCLONAL ANTIBODY, BY DRUG TYPE

11.2.1.1.2.1 GENERIC

11.2.1.1.2.2 BRANDED

11.2.1.1.2.2.1. OCREVUS

11.2.1.1.2.2.2. TYSABRI

11.2.1.1.2.2.3. ZENAPAX

11.2.1.2. IMMUNOMODULATOR DRUGS

11.2.1.2.1. IMMUNOMODULATOR DRUGS, BY DRUG

11.2.1.2.1.1 GLATIRAMER

11.2.1.2.1.2 CLADRIBINE

11.2.1.2.1.3 TERIFLUNOMIDE

11.2.1.2.1.4 DIMETHYL FUMARATE

11.2.1.2.1.5 OTHERS

11.2.1.2.2. IMMUNOMODULATOR DRUGS, BY DRUG TYPE

11.2.1.2.2.1 GENERIC

11.2.1.2.2.2 BRANDED

11.2.1.2.2.2.1. GLATOPA

11.2.1.2.2.2.2. COPAXONE

11.2.1.2.2.2.3. MAVENCLAD

11.2.1.2.2.2.4. OTHERS

11.2.1.3. SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS

11.2.1.3.1. SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS, BY TYPE

11.2.1.3.1.1 PONESIMOD

11.2.1.3.1.2 FINGOLIMOD

11.2.1.3.1.3 SIPONIMOD

11.2.1.3.1.4 OZANIMOD

11.2.1.3.1.5 OTHERS

11.2.1.3.2. SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS, BY DRUG TYPE

11.2.1.3.2.1 GENERIC

11.2.1.3.2.2 BRANDED

11.2.1.3.2.2.1. PONVORY

11.2.1.3.2.2.2. ZEPOSIA

11.2.1.3.2.2.3. MAYZENT

11.2.1.3.2.2.4. ZEPOSIA

11.2.1.4. ANTI CANCER DRUGS

11.2.1.4.1. ANTI CANCER DRUGS, BY TYPE

11.2.1.4.1.1 MITOXANTRONE

11.2.1.4.1.2 CYCLOPHOSPHAMIDE

11.2.1.4.1.3 MELPHALAN FLUFENAMIDE

11.2.1.4.1.4 OTHERS

11.2.1.4.2. ANTI CANCER DRUGS, BY DRUG TYPE

11.2.1.4.2.1 GENERIC

11.2.1.4.2.2 BRANDED

11.2.1.4.2.2.1. PEPAXTO

11.2.1.4.2.2.2. CYTOXAN

11.2.1.4.2.2.3. NEOSAR

11.2.1.4.2.2.4. OTHERS

11.2.1.5. INTERFERONE

11.2.1.5.1. INTERFERONE, BY TYPE

11.2.1.5.1.1 INTERFERON BETA-1B

11.2.1.5.1.2 INTERFERON BETA-1A

11.2.1.5.1.3 PEGYLATED INTERFERON BETA-1A

11.2.1.5.1.4 OTHERS

11.2.1.5.2. INTERFERONE, BY DRUG TYPE

11.2.1.5.2.1 GENERIC

11.2.1.5.2.2 BRANDED

11.2.1.5.2.2.1. ROFERON

11.2.1.5.2.2.2. VIRAFERON

11.2.1.5.2.2.3. AVONEX

11.2.1.5.2.2.4. BETASERON

 

11.2.1.6. IMMUNOSUPPRESSANTS

11.2.1.6.1. IMMUNOSUPPRESSANTS, BY TYPE

11.2.1.6.1.1 AZATHIOPRINE

11.2.1.6.1.2 METHOTREXATE

11.2.1.6.1.3 OTHERS

11.2.1.6.2. IMMUNOSUPPRESSANTS, BY DRUG TYPE

11.2.1.6.2.1 AZASAN

11.2.1.6.2.2 IMURAN

11.2.1.6.2.3 REDITREX

11.2.1.6.2.4 TREXALL

11.2.1.6.2.5 XATMEP

11.2.2 SYMPTOMATIC THERAPIES

11.2.2.1. MUSCLE RELAXANTS

11.2.2.1.1. MUSCLE RELAXANTS, BY TYPE

11.2.2.1.1.1 BACLOFEN

11.2.2.1.1.2 TIZANIDINE

11.2.2.1.1.3 CYCLOBENZAPRINE

11.2.2.1.1.4 OTHERS

11.2.2.1.2. MUSCLE RELAXANTS, BY DRUG TYPE

11.2.2.1.2.1 GENERIC

11.2.2.1.2.2 BRANDED

11.2.2.1.2.2.1. LIORESAL

11.2.2.1.2.2.2. ZANAFLEX

11.2.2.1.2.2.3. FLEXERIL

11.2.2.2. FATIGUE MEDICATIONS

11.2.2.2.1. FATIGUE MEDICATIONS, BY TYPE

11.2.2.2.1.1 AMANTADINE

11.2.2.2.1.2 MODAFINIL

11.2.2.2.1.3 METHYLPHENIDATE

11.2.2.2.1.4 OTHERS

11.2.2.2.2. FATIGUE MEDICATIONS, BY DRUG TYPE

11.2.2.2.2.1 GENERIC

11.2.2.2.2.2 BRANDED

11.2.2.2.2.2.1. GOCOVRI

11.2.2.2.2.2.2. PROVIGIL

11.2.2.2.2.2.3. RITALIN

 

11.2.2.3. NEUROPATHIC PAIN

11.2.2.3.1. GABAPENTIN

11.2.2.3.2. CARBAMAZEPINE

11.2.2.3.3. AMITRIPTYLINE

11.2.2.3.4. OTHERS

11.2.2.4. CORTICOSTEROIDS

11.2.2.4.1. PREDNISONE

11.2.2.4.2. METHYLPREDNISOLONE

11.2.2.4.3. DEXAMETHASONE

11.2.2.4.4. PREDNISOLONE

11.2.2.4.5. BETAMETHASONE

11.2.2.4.6. OTHERS

11.3 PHYSIOTHERAPY

11.3.1 MANUAL THERAPY

11.3.2 SPECIALIZED TREATMENTS

11.3.3 JOINT MOBILIZATION TECHNIQUES

11.3.4 SUSPENSION THERAPY

11.3.5 RELAXATION TECHNIQUES

11.3.6 POSTURE CORRECTION METHODS

11.4 PLASMAPHERESIS

11.4.1 PLASMA EXCHANGE (PE)

11.4.2 DOUBLE-MEMBRANE-FILTRATION PLASMAPHERESIS (DFP)

11.4.3 ADSORPTION PLASMAPHERESIS

11.5 OTHERS

12 GLOBAL MULTIPLE SCLEROSIS MARKET , BY DRUG TYPE

12.1 OVERVIEW

12.2 GENERIC

12.3 BRANDED

12.3.1 OCREVUS

12.3.2 TYSABRI

12.3.3 ZENAPAX

12.3.4 GLATOPA

12.3.5 COPAXONE

12.3.6 MAVENCLAD

12.3.7 PONVORY

12.3.8 ZEPOSIA

12.3.9 MAYZENT

12.3.10 ZEPOSIA

12.3.11 PEPAXTO

12.3.12 CYTOXAN

12.3.13 NEOSAR

12.3.14 ROFERON

12.3.15 VIRAFERON

12.3.16 AVONEX

12.3.17 BETASERON

12.3.18 BACLOFEN

12.3.19 TIZANIDINE

12.3.20 CYCLOBENZAPRINE

12.3.21 OTHERS

13 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

13.1 OVERVIEW

13.2 ORAL

13.2.1 TABLET

13.2.2 CAPSULE

13.2.3 OTHERS

13.3 PARENTERAL

13.3.1 INTRAVENOUS

13.3.2 SUBCUTANEOUS

13.3.3 OTHERS

13.4 OTHERS

14 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, BY PRESCRIPTION TYPE

14.1 OVERVIEW

14.2 OVER THE COUNTER

14.3 PRESCRIPTION

15 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, BY AGE GROUP

15.1 OVERVIEW

15.2 CHILDREN

15.3 ADULTS

15.4 GERIATRIC

16 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, BY GENDER

16.1 OVERVIEW

16.2 MALE

16.3 FEMALE

 

17 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER

17.1 OVERVIEW

17.2 HOSPITALS

17.3 SPECIALTY CLINICS

17.4 HOME HEALTHCARE

17.5 AMBULATORY SURGICAL CENTERS

17.6 OTHERS

18 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

18.1 OVERVIEW

18.2 HOSPITAL PHARMACY

18.3 RETAIL PHARMACY

18.3.1 ONLINE STORES

18.3.2 PHARMACY STORES

18.4 OTHERS

19 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, BY GEOGRAPHY

EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)

19.1 EUROPE

19.1.1 GERMANY

19.1.2 U.K.

19.1.3 ITALY

19.1.4 FRANCE

19.1.5 SPAIN

19.1.6 RUSSIA

19.1.7 SWITZERLAND

19.1.8 TURKEY

19.1.9 BELGIUM

19.1.10 NETHERLANDS

19.1.11 DENMARK

19.1.12 SWEDEN

19.1.13 POLAND

19.1.14 NORWAY

19.1.15 FINLAND

19.1.16 REST OF EUROPE

 

20 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, COMPANY LANDSCAPE

20.1 COMPANY SHARE ANALYSIS: GLOBAL

20.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

20.3 COMPANY SHARE ANALYSIS: EUROPE

20.4 COMPANY SHARE ANALYSIS: EUROPE

20.5 MERGERS & ACQUISITIONS

20.6 NEW PRODUCT DEVELOPMENT & APPROVALS

20.7 EXPANSIONS

20.8 REGULATORY CHANGES

20.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS

21 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, SWOT AND DBMR ANALYSIS

22 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, COMPANY PROFILE

22.1 BIOGEN

22.1.1 COMPANY OVERVIEW

22.1.2 REVENUE ANALYSIS

22.1.3 GEOGRAPHIC PRESENCE

22.1.4 PRODUCT PORTFOLIO

22.1.5 RECENT DEVELOPMENTS

22.2 TEVA NEUROSCIENCE, INC.

22.2.1 COMPANY OVERVIEW

22.2.2 REVENUE ANALYSIS

22.2.3 GEOGRAPHIC PRESENCE

22.2.4 PRODUCT PORTFOLIO

22.2.5 RECENT DEVELOPMENTS

22.3 VIATRIS INC.

22.3.1 COMPANY OVERVIEW

22.3.2 REVENUE ANALYSIS

22.3.3 GEOGRAPHIC PRESENCE

22.3.4 PRODUCT PORTFOLIO

22.3.5 RECENT DEVELOPMENTS

22.4 NOVARTIS AG

22.4.1 COMPANY OVERVIEW

22.4.2 REVENUE ANALYSIS

22.4.3 GEOGRAPHIC PRESENCE

22.4.4 PRODUCT PORTFOLIO

22.4.5 RECENT DEVELOPMENTS

 

22.5 MERCK KGAA

22.5.1 COMPANY OVERVIEW

22.5.2 REVENUE ANALYSIS

22.5.3 GEOGRAPHIC PRESENCE

22.5.4 PRODUCT PORTFOLIO

22.5.5 RECENT DEVELOPMENTS

22.6 GLENMARK PHARMACEUTICALS LTD

22.6.1 COMPANY OVERVIEW

22.6.2 REVENUE ANALYSIS

22.6.3 GEOGRAPHIC PRESENCE

22.6.4 PRODUCT PORTFOLIO

22.6.5 RECENT DEVELOPMENTS

22.7 LUPIN

22.7.1 COMPANY OVERVIEW

22.7.2 REVENUE ANALYSIS

22.7.3 GEOGRAPHIC PRESENCE

22.7.4 PRODUCT PORTFOLIO

22.7.5 RECENT DEVELOPMENTS

22.8 CIPLA INC

22.8.1 COMPANY OVERVIEW

22.8.2 REVENUE ANALYSIS

22.8.3 GEOGRAPHIC PRESENCE

22.8.4 PRODUCT PORTFOLIO

22.8.5 RECENT DEVELOPMENTS

22.9 SANOFI

22.9.1 COMPANY OVERVIEW

22.9.2 REVENUE ANALYSIS

22.9.3 GEOGRAPHIC PRESENCE

22.9.4 PRODUCT PORTFOLIO

22.9.5 RECENT DEVELOPMENTS

22.1 BAYER

22.10.1 COMPANY OVERVIEW

22.10.2 REVENUE ANALYSIS

22.10.3 GEOGRAPHIC PRESENCE

22.10.4 PRODUCT PORTFOLIO

22.10.5 RECENT DEVELOPMENTS

 

22.11 ABBVIE, INC

22.11.1 COMPANY OVERVIEW

22.11.2 REVENUE ANALYSIS

22.11.3 GEOGRAPHIC PRESENCE

22.11.4 PRODUCT PORTFOLIO

22.11.5 RECENT DEVELOPMENTS

22.12 ABBOTT

22.12.1 COMPANY OVERVIEW

22.12.2 REVENUE ANALYSIS

22.12.3 GEOGRAPHIC PRESENCE

22.12.4 PRODUCT PORTFOLIO

22.12.5 RECENT DEVELOPMENTS

22.13 F. HOFFMANN-LA ROCHE LTD

22.13.1 COMPANY OVERVIEW

22.13.2 REVENUE ANALYSIS

22.13.3 GEOGRAPHIC PRESENCE

22.13.4 PRODUCT PORTFOLIO

22.13.5 RECENT DEVELOPMENTS

22.14 BRISTOL MYERS SQUIBB

22.14.1 COMPANY OVERVIEW

22.14.2 REVENUE ANALYSIS

22.14.3 GEOGRAPHIC PRESENCE

22.14.4 PRODUCT PORTFOLIO

22.14.5 RECENT DEVELOPMENTS

22.15 TG THERAPEUTICS, INC

22.15.1 COMPANY OVERVIEW

22.15.2 REVENUE ANALYSIS

22.15.3 GEOGRAPHIC PRESENCE

22.15.4 PRODUCT PORTFOLIO

22.15.5 RECENT DEVELOPMENTS

NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST

23 RELATED REPORTS

24 CONCLUSION

25 QUESTIONNAIRE

26 ABOUT DATA BRIDGE MARKET RESEARCH

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATION

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 KEY TAKEAWAYS

2.2 ARRIVING AT THE EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET

2.2.1 VENDOR POSITIONING GRID

2.2.2 TECHNOLOGY LIFE LINE CURVE

2.2.3 TRIPOD DATA VALIDATION MODEL

2.2.4 MARKET GUIDE

2.2.5 MULTIVARIATE MODELLING

2.2.6 TOP TO BOTTOM ANALYSIS

2.2.7 CHALLENGE MATRIX

2.2.8 APPLICATION COVERAGE GRID

2.2.9 STANDARDS OF MEASUREMENT

2.2.10 VENDOR SHARE ANALYSIS

2.2.11 SALES VOLUME DATA

2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS

2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES

2.3 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET: RESEARCH SNAPSHOT

2.4 ASSUMPTIONS

3 MARKET OVERVIEW

3.1 DRIVERS

3.2 RESTRAINTS

3.3 OPPORTUNITIES

3.4 CHALLENGES

4 EXECUTIVE SUMMARY

 

5 PREMIUM INSIGHTS

5.1 PESTEL ANALYSIS

5.2 PORTER’S FIVE FORCES MODEL

5.3 EVOLUTION MS TREATMENT MARKET IN EUROPE LAST 10-20 YEARS

6 INDUSTRY INSIGHTS

6.1 PATENT ANALYSIS

6.1.1 PATENT LANDSCAPE

6.1.2 USPTO NUMBER

6.1.3 PATENT EXPIRY

6.1.4 EPIO NUMBER

6.1.5 PATENT STRENGTH AND QUALITY

6.1.6 PATENT CLAIMS

6.1.7 PATENT CITATIONS

6.1.8 PATENT LITIGATION AND LICENSING

6.1.9 FILE OF PATENT

6.1.10 PATENT RECEIVED CONTRIES

6.1.11 TECHNOLOGY BACKGROUND

6.2 DRUG TREATMENT RATE BY MATURED MARKETS

6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES

6.4 PATIENT FLOW DIAGRAM

6.5 KEY PRICING STRATEGIES

6.6 KEY PATIENT ENROLLMENT STRATEGIES

6.7 INTERVIEWS WITH SPECIALIST

6.8 OTHER KOL SNAPSHOTS

7 EPIDEMIOLOGY

7.1 INCIDENCE OF ALL BY GENDER

7.2 TREATMENT RATE

7.3 MORTALITY RATE

7.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL

7.5 PATIENT TREATMENT SUCCESS RATES

8 MERGERS AND ACQUISITION

8.1 LICENSING

8.2 COMMERCIALIZATION AGREEMENTS

 

9 REGULATORY FRAMEWORK

9.1 REGULATORY APPROVAL PROCESS

9.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL

9.3 REGULATORY APPROVAL PATHWAYS

9.4 LICENSING AND REGISTRATION

9.5 POST-MARKETING SURVEILLANCE

9.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES

10 PIPELINE ANALYSIS

10.1 CLINICAL TRIALS AND PHASE ANALYSIS

10.2 DRUG THERAPY PIPELINE

10.3 PHASE III CANDIDATES

10.4 PHASE II CANDIDATES

10.5 PHASE I CANDIDATES

10.6 OTHERS (PRE-CLINICAL AND RESEARCH)

TABLE 1 EUROPE CLINICAL TRIAL MARKET FOR MULTIPLE SCLEROSIS TREATMENT MARKET

Company Name Therapeutic Area

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

TABLE 2 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE MULTIPLE SCLEROSIS TREATMENT MARKET

Phase Number of Projects

Preclinical/Research Projects XX

Clinical Development XX

Phase I XX

Phase II XX

Phase III XX

U.S. Filed/Approved But Not Yet Marketed XX

Total XX

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

TABLE 3 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE MULTIPLE SCLEROSIS TREATMENT MARKET

Therapeutic Area Preclinical/ Research Project

XX XX

XX XX

XX XX

XX XX

XX XX

Total Projects XX

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

TABLE 4 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE MULTIPLE SCLEROSIS TREATMENT MARKET

Technology Preclinical/ Research Project

XX XX

XX XX

XX XX

XX XX

XX XX

Total Projects XX

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

 

FIGURE 1 TOP ENTITIES BASED ON R&D GLANCE FOR MULTIPLE SCLEROSIS TREATMENT MARKET

 

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

11 MARKETED DRUG ANALYSIS

11.1 DRUG

11.1.1 BRAND NAME

11.1.2 GENERICS NAME

11.2 THERAPEUTIC INDICTION

11.3 PHARMACOLOGICAL CLASS OF THE DRUG

11.4 DRUG PRIMARY INDICATION

11.5 MARKET STATUS

11.6 MEDICATION TYPE

11.7 DRUG DOSAGES FORM

11.8 DOSAGES AVAILABILITY

11.9 DRUG ROUTE OF ADMINISTRATION

11.1 DOSING FREQUENCY

11.11 DRUG INSIGHT

11.12 AN OVERVIEW OF THE DRUG DEVELOPMENT ACTIVITIES SUCH AS REGULATORY MILSTONE, SAFETY DATA AND EFFICACY DATA, MARKET EXCLUSIVITY DATA.

11.12.1 FORECAST MARKET OUTLOOK

11.12.2 CROSS COMPETITION

11.12.3 THERAPEUTIC PORTFOLIO

11.12.4 CURRENT DEVELOPMENT SCENARIO

12 MARKET ACCESS

12.1 10-YEAR MARKET FORECAST

12.2 CLINICAL TRIAL RECENT UPDATES

12.3 ANNUAL NEW FDA APPROVED DRUGS

12.4 DRUGS MANUFACTURER AND DEALS

12.5 MAJOR DRUG UPTAKE

12.6 CURRENT TREATMENT PRACTICES

12.7 IMPACT OF UPCOMING THERAPY

13 R & D ANALYSIS

13.1 COMPARATIVE ANALYSIS

13.2 DRUG DEVELOPMENTAL LANDSCAPE

13.3 IN-DEPTH INSIGHTS ON REGULATORY MILESTONES

13.4 THERAPEUTIC ASSESSMENT

13.5 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS

14 MARKET OVERVIEW

14.1 DRIVERS

14.2 RESTRAINTS

14.3 OPPORTUNITIES

14.4 CHALLENGES

15 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, BY TYPE

15.1 OVERVIEW

15.2 CLINICALLY ISOLATED SYNDROME (CIS)

15.3 RELAPSING–REMITTING MULTIPLE SCLEROSIS (RRMS)

15.4 SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS (SPMS)

15.5 PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS (PPMS)

15.6 SEVERE RELAPSING–REMITTING MULTIPLE SCLEROSIS (RES)

 

16 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET,BY THERAPEUTICS

16.1 OVERVIEW

16.2 APPROVED/ MARKETED MEDICATION

16.2.1 PREVENTIVE THERAPIES

16.2.1.1. ORAL MEDICATION

16.2.1.1.1. TECFIDERA

16.2.1.1.2. GILENYA

16.2.1.1.3. AUBAGIO

16.2.1.1.4. MAVENCLAD

16.2.1.1.5. MAYZENT

16.2.1.1.6. VUMERITY

16.2.1.1.7. OTHERS

16.2.1.2. INJECTABLE MEDICATION

16.2.1.2.1. INTERFERON BETA-1A

16.2.1.2.1.1 AVONEX

16.2.1.2.1.2 REBIF

16.2.1.2.1.3 OTHERS

16.2.1.2.2. GLATIRAMER ACETATE

16.2.1.2.2.1 COPAXONE

16.2.1.2.2.2 GLATOPA

16.2.1.2.2.3 OTHERS

16.2.1.2.3. INTERFERON BETA-1B

16.2.1.2.3.1 BETASERON

16.2.1.2.3.2 EXTAVIA

16.2.1.2.4. PLEGRIDY/PEGINTERFERON BETA-1A

16.2.1.2.5. CHEMOTHERAPY DRUG

16.2.1.2.6. MONOCLONAL ANTIBODIES

16.2.1.3. INFUSED MEDICATION

16.2.1.3.1. TYSABRI

16.2.1.3.2. OCREVUS

16.2.1.3.3. LEMTRADA

16.2.1.3.4. MITOXANTRONE

16.2.1.3.5. NOVANTRONE

16.2.1.3.6. OTHERS

16.2.1.4. HAEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)

 

16.2.2 ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS

16.2.2.1. CORTICOSTEROIDS

16.2.2.1.1. ORAL PREDNISONE

16.2.2.1.2. METHYLPREDNISOLONE

16.2.2.1.3. DEXAMETHASONE

16.2.2.1.4. PREDNISOLONE

16.2.2.1.5. BETAMETHASONE

16.2.2.1.6. OTHERS

16.2.2.2. BENZODIAZEPINES

16.2.2.2.1. CLONAZEPAM

16.2.2.2.2. DIAZEPAM

16.2.2.2.3. OTHERS

16.2.2.3. IMMUNOSUPPRESSANTS

16.2.2.3.1. AZATHIOPRINE

16.2.2.3.2. CYCLOPHOSPHAMIDE

16.2.2.3.3. METHOTREXATE

16.2.2.3.4. MITOXANTRONE

16.2.2.3.5. OTHERS

16.2.2.4. SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATORS

16.2.2.4.1. SIPONIMOD

16.2.2.4.2. FINGOLIMOD

16.2.2.4.3. OZANIMOD

16.2.2.4.4. OTHERS

16.2.2.5. DOPAMINE AGONISTS

16.2.2.5.1. OSMOLEX ER

16.2.2.5.2. GOCOVRI

16.2.2.5.3. OTHERS

16.2.2.6. NEUROMUSCULAR BLOCKERS

16.2.2.6.1. BOTOX

16.2.2.6.2. BOTOX COSMETIC

16.2.2.6.3. BOTULINUM TOXIN

16.2.2.7. ADRENOCORTICOTROPIC HORMONE

16.2.2.8. INTRAVENOUS IMMUNOGLOBULIN

16.2.2.9. PLASMAPHERESIS

16.2.2.10. OTHERS

 

16.2.3 SYMPTOMATIC THERAPIES

16.2.3.1. MUSCLE RELAXANTS

16.2.3.1.1. LIORESAL

16.2.3.1.2. ZANAFLEX

16.2.3.1.3. OTHERS

16.2.3.2. FATIGUE MEDICATIONS

16.2.3.2.1. GOCOVRI

16.2.3.2.2. OSMOLEX

16.2.3.2.3. PROVIGIL

16.2.3.2.4. RITALIN

16.2.3.2.5. OTHERS

16.2.3.3. STIMULANTS

16.2.3.3.1. MODAFINIL

16.2.3.3.2. ARMODAFINIL

16.2.3.3.3. OTHERS

16.2.3.4. ANTICONVULSANTS

16.2.3.4.1. GABAPENTIN

16.2.3.4.2. CARBAMAZEPINE

16.2.3.4.3. PREGABALIN

16.2.3.4.4. TOPIRAMATE

16.2.3.4.5. OTHERS

16.2.3.5. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS

16.2.3.5.1. IBUPROFEN

16.2.3.5.2. NAPROXEN

16.2.3.5.3. DICLOFENAC

16.2.3.5.4. INDOMETHACIN

16.2.3.5.5. OTHERS

16.2.3.6. ANTIDIARRHEALS

16.2.3.7. POTASSIUM CHANNEL BLOCKERS

16.2.3.8. PHYSIOTHERAPY

16.2.3.9. LAXATIVES

16.2.3.10. OTHERS

16.3 PIPELINE DRUGS

16.3.1 SCM-0101

16.3.2 IMCY-MS-001

16.3.3 PIPE-307

16.3.4 ATA188

16.3.5 WP1303

16.3.6 FORALUMAB

16.3.7 OTHERS

17 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE

17.1 OVERVIEW

17.2 BRANDED

17.2.1 TECFIDERA

17.2.2 GILENYA

17.2.3 AUBAGIO

17.2.4 AVONEX

17.2.5 TYSABRI

17.2.6 REBIF

17.2.7 COPAXONE

17.2.8 8 BETASERON

17.2.9 AMPYRA/FAMPYRA

17.2.10 OTHERS

17.3 GENERICS

18 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET,BY ROUTE OF ADMINISTRATION

18.1 OVERVIEW

18.2 ORAL

18.2.1 TABLETS

18.2.2 CAPSULES

18.2.3 OTHERS

18.3 PARENTERAL

18.3.1 INTRAVENOUS

18.3.2 SUBCUTANEOUS

18.3.3 OTHERS

18.4 OTHERS

19 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET,BY AGE GROUP

19.1 OVERVIEW

19.2 PEDIATRIC

19.2.1 MALE

19.2.2 FEMALE

19.3 ADULT

19.3.1 MALE

19.3.2 FEMALE

19.4 GERIATRIC

19.4.1 MALE

19.4.2 FEMALE

 

20 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET,BY GENDER

20.1 OVERVIEW

20.2 MALE

20.3 FEMALE

21 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER

21.1 OVERVIEW

21.2 HOSPITALS

21.2.1 PUBLIC

21.2.1.1. TIER 1

21.2.1.2. TIER 2

21.2.1.3. TIER 3

21.2.2 PRIVATE

21.2.2.1. TIER 1

21.2.2.2. TIER 2

21.2.2.3. TIER 3

21.3 HOME HELATHCARE

21.4 SPECIALITY CENTRE

21.5 ACADEMIC AND RESEARCH INSTITUTES

21.6 OTHERS

22 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

22.1 OVERVIEW

22.2 DIRECT TENDERS

22.3 RETAIL SALES

22.3.1 ONLINE

22.3.1.1. E-STORES

22.3.1.2. COMPANY WEBSITE

22.3.1.3. OTHERS

22.3.2 OFFLINE

22.3.2.1. HOSPITAL PHARMACY

22.3.2.2. RETAIL PHARMACY

22.3.2.3. OTHERS

22.4 OTHERS

 

23 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, COMPANY LANDSCAPE

23.1 COMPANY SHARE ANALYSIS: EUROPE

23.2 MERGERS & ACQUISITIONS

23.3 NEW PRODUCT DEVELOPMENT & APPROVALS

23.4 EXPANSIONS

23.5 REGULATORY CHANGES

23.6 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS

24 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, SWOT AND DBMR ANALYSIS

25 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, BY COUNTRY

EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)

25.1 EUROPE

25.1.1 GERMANY

25.1.2 FRANCE

25.1.3 U.K.

25.1.4 ITALY

25.1.5 SPAIN

25.1.6 RUSSIA

25.1.7 TURKEY

25.1.8 BELGIUM

25.1.9 DENMARK

25.1.10 NETHERLANDS

25.1.11 SWITZERLAND

25.1.12 SWEDEN

25.1.13 POLAND

25.1.14 NORWAY

25.1.15 FINLAND

25.1.16 REST OF EUROPE

25.2 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES

 

26 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, COMPANY PROFILE

26.1 MARKETED /APPROVED MANUFRACTURES

26.1.1 BIOGEN

26.1.1.1. COMPANY OVERVIEW

26.1.1.2. REVENUE ANALYSIS

26.1.1.3. GEOGRAPHIC PRESENCE

26.1.1.4. PRODUCT PORTFOLIO

26.1.1.5. RECENT DEVELOPMENTS

26.1.2 NOVARTIS AG

26.1.2.1. COMPANY OVERVIEW

26.1.2.2. REVENUE ANALYSIS

26.1.2.3. GEOGRAPHIC PRESENCE

26.1.2.4. PRODUCT PORTFOLIO

26.1.2.5. RECENT DEVELOPMENTS

26.1.3 GENZYME CORPORATION (A SUBSIDIARY OF SANOFI)

26.1.3.1. COMPANY OVERVIEW

26.1.3.2. REVENUE ANALYSIS

26.1.3.3. GEOGRAPHIC PRESENCE

26.1.3.4. PRODUCT PORTFOLIO

26.1.3.5. RECENT DEVELOPMENTS

26.1.4 MERCK KGAA

26.1.4.1. COMPANY OVERVIEW

26.1.4.2. REVENUE ANALYSIS

26.1.4.3. GEOGRAPHIC PRESENCE

26.1.4.4. PRODUCT PORTFOLIO

26.1.4.5. RECENT DEVELOPMENTS

26.1.5 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICALS INDUSTRIES LTD.)

26.1.5.1. COMPANY OVERVIEW

26.1.5.2. REVENUE ANALYSIS

26.1.5.3. GEOGRAPHIC PRESENCE

26.1.5.4. PRODUCT PORTFOLIO

26.1.5.5. RECENT DEVELOPMENTS

26.1.6 F. HOFFMANN-LA ROCHE LTD

26.1.6.1. COMPANY OVERVIEW

26.1.6.2. REVENUE ANALYSIS

26.1.6.3. GEOGRAPHIC PRESENCE

26.1.6.4. PRODUCT PORTFOLIO

26.1.6.5. RECENT DEVELOPMENTS

 

26.1.7 ACORDA THERAPEUTICS, INC

26.1.7.1. COMPANY OVERVIEW

26.1.7.2. REVENUE ANALYSIS

26.1.7.3. GEOGRAPHIC PRESENCE

26.1.7.4. PRODUCT PORTFOLIO

26.1.7.5. RECENT DEVELOPMENTS

26.1.8 AMNEAL PHARMACEUTICALS LLC

26.1.8.1. COMPANY OVERVIEW

26.1.8.2. REVENUE ANALYSIS

26.1.8.3. GEOGRAPHIC PRESENCE

26.1.8.4. PRODUCT PORTFOLIO

26.1.8.5. RECENT DEVELOPMENTS

26.1.9 BAYER AG

26.1.9.1. COMPANY OVERVIEW

26.1.9.2. REVENUE ANALYSIS

26.1.9.3. GEOGRAPHIC PRESENCE

26.1.9.4. PRODUCT PORTFOLIO

26.1.9.5. RECENT DEVELOPMENTS

26.1.10 CELGENE CORPORATION (A SUBSIDIARY OF BRISTOL-MYERS SQUIBB COMPANY)

26.1.10.1. COMPANY OVERVIEW

26.1.10.2. REVENUE ANALYSIS

26.1.10.3. GEOGRAPHIC PRESENCE

26.1.10.4. PRODUCT PORTFOLIO

26.1.10.5. RECENT DEVELOPMENTS

26.1.11 HIKMA PHARMACEUTICALS PLC

26.1.11.1. COMPANY OVERVIEW

26.1.11.2. REVENUE ANALYSIS

26.1.11.3. GEOGRAPHIC PRESENCE

26.1.11.4. PRODUCT PORTFOLIO

26.1.11.5. RECENT DEVELOPMENTS

26.1.12 MALLINCKRODT PHARMACEUTICALS

26.1.12.1. COMPANY OVERVIEW

26.1.12.2. REVENUE ANALYSIS

26.1.12.3. GEOGRAPHIC PRESENCE

26.1.12.4. PRODUCT PORTFOLIO

26.1.12.5. RECENT DEVELOPMENTS

 

26.1.13 VITARIS INC.

26.1.13.1. COMPANY OVERVIEW

26.1.13.2. REVENUE ANALYSIS

26.1.13.3. GEOGRAPHIC PRESENCE

26.1.13.4. PRODUCT PORTFOLIO

26.1.13.5. RECENT DEVELOPMENTS

26.1.14 PAR PHARMACEUTICAL (A SUBSIDIARY OF ENDO INTERNATIONAL PLC)

26.1.14.1. COMPANY OVERVIEW

26.1.14.2. REVENUE ANALYSIS

26.1.14.3. GEOGRAPHIC PRESENCE

26.1.14.4. PRODUCT PORTFOLIO

26.1.14.5. RECENT DEVELOPMENTS

26.1.15 PFIZER INC.

26.1.15.1. COMPANY OVERVIEW

26.1.15.2. REVENUE ANALYSIS

26.1.15.3. GEOGRAPHIC PRESENCE

26.1.15.4. PRODUCT PORTFOLIO

26.1.15.5. RECENT DEVELOPMENTS

26.1.16 ZYDUS PHARMACEUTICALS, INC. (A SUBSIDIARY OF ZYDUS CADILA)

26.1.16.1. COMPANY OVERVIEW

26.1.16.2. REVENUE ANALYSIS

26.1.16.3. GEOGRAPHIC PRESENCE

26.1.16.4. PRODUCT PORTFOLIO

26.1.16.5. RECENT DEVELOPMENTS

26.1.17 JOHNSON & JOHNSON CONSUMER INC.

26.1.17.1. COMPANY OVERVIEW

26.1.17.2. PRODUCT PORTFOLIO

26.1.17.3. REVENUE ANALYSIS

26.1.17.4. GEOGRAPHIC PRESENCE

26.1.17.5. PRODUCT PORTFOLIO

26.1.18 PERRIGO COMPANY PLC,

26.1.18.1. COMPANY OVERVIEW

26.1.18.2. PRODUCT PORTFOLIO

26.1.18.3. REVENUE ANALYSIS

26.1.18.4. GEOGRAPHIC PRESENCE

26.1.18.5. PRODUCT PORTFOLIO

 

26.1.19 GLENMARK PHARMACEUTICAL INC., USA

26.1.19.1. COMPANY OVERVIEW

26.1.19.2. REVENUE ANALYSIS

26.1.19.3. GEOGRAPHIC PRESENCE

26.1.19.4. PRODUCT PORTFOLIO

26.1.19.5. RECENT DEVELOPMENTS

26.1.20 GLAXOSMITHKLINE PLC.

26.1.20.1. COMPANY OVERVIEW

26.1.20.2. PRODUCT PORTFOLIO

26.1.20.3. REVENUE ANALYSIS

26.1.20.4. GEOGRAPHIC PRESENCE

26.1.20.5. PRODUCT PORTFOLIO

26.2 PIPELINE COMPANIES

26.2.1 IMCYSE

26.2.1.1. COMPANY OVERVIEW

26.2.1.2. PRODUCT PORTFOLIO

26.2.1.3. REVENUE ANALYSIS

26.2.1.4. GEOGRAPHIC PRESENCE

26.2.1.5. PRODUCT PORTFOLIO

26.2.2 WORG PHARMACEUTICALS (ZHEJIANG) CO., LTD.

26.2.2.1. COMPANY OVERVIEW

26.2.2.2. PRODUCT PORTFOLIO

26.2.2.3. REVENUE ANALYSIS

26.2.2.4. GEOGRAPHIC PRESENCE

26.2.2.5. PRODUCT PORTFOLIO

26.2.3 TIZIANA LIFE SCIENCES

26.2.3.1. COMPANY OVERVIEW

26.2.3.2. PRODUCT PORTFOLIO

26.2.3.3. REVENUE ANALYSIS

26.2.3.4. GEOGRAPHIC PRESENCE

26.2.3.5. PRODUCT PORTFOLIO

27 RELATED REPORTS

28 CONCLUSION

29 QUESTIONNAIRE

30 ABOUT DATA BRIDGE MARKET RESEARCH